Skip to main content

Enovis™ Announces Leadership Change to International Surgical Business

Written by Customer Service on . Posted in Public Companies.

Wilmington, DE, Jan. 17, 2025 (GLOBE NEWSWIRE) — Enovis™, a global medical technology innovator headquartered in the United States, announced recently that Davide Visentin will succeed Dr. Benjamin Reinmann as President of Enovis International Surgical, effective March 1, 2025.

Visentin is a successful MedTech executive who comes to Enovis with more than 20 years of healthcare experience. Most recently, he was the Vice President and General Manager of the Integrated Diagnostic Solutions Business Unit for BD, where he managed more than 700 employees across 50 countries and gained market share in a very competitive market. Prior to BD, Visentin served as Vice President and General Manager of Europe for Stryker’s Joint Replacement and Robotic Division, and Vice President, EMEA, for Johnson & Johnson Depuy Synthes.

“Under Benjamin Reinmann’s leadership, Enovis has created a world-class International Surgical Business. We sincerely thank Benjamin for his numerous contributions to the growth and success of both Enovis and Mathys, and especially throughout the critical integration of legacy companies Mathys and LimaCorporate,” said Louie Vogt, Group President of Enovis’ Reconstructive Business Group. “We are very excited to welcome Davide to Enovis. He is a dynamic leader with a strong track record of successfully growing businesses, a true passion for orthopedics, and the experience and playbook to take our business to the next level.”

Visentin has a degree in Computer Science from the University of Milan. He will primarily spend his time in Villanova, Italy, and Bettlach, Switzerland.

“We continue to make great progress with building and growing our International Surgical Business into a global orthopedics leader that is thriving because of our team’s commitment to excellence and to going above and beyond every day to create better together,” added Vogt. “The momentum we created in 2024 puts us in a strong position to advance our strategic goals, continue gaining market share and drive growth through innovation, all with the ultimate goal of improving patient outcomes.”

About Enovis

Enovis™ (NYSE: ENOV) is a global medical technology innovator dedicated to improving lives by developing clinically differentiated solutions that enhance patient outcomes and restore motion for life. We partner with the brightest minds in health to advance care that is smarter, personalized, and more effective, while improving operational efficiency for surgeons and clinicians around the world. Enovis solutions impact the well-being of millions of patients wherever they are on their pathway to health. Learn more about Enovis at www.enovis.com.

Media Contact

Lee Griffin
Vice President, Global Marketing Communications & Digital, Enovis
+1 (469) 794-9760
Lee.Griffin@enovis.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.